Overview
Hodgkin disease involving lymph nodes of the lower limb is a rare manifestation of Hodgkin lymphoma, characterized by painless lymphadenopathy primarily localized to the inguinal, femoral, or popliteal regions. [Not directly addressed in provided abstracts]Diagnosis
Clinical examination revealing painless lymphadenopathy in lower limb lymph nodes.
Imaging studies (e.g., CT, MRI) to assess extent and involvement.
Lymph node biopsy for histopathological confirmation, including Reed-Sternberg cells.
Staging workup including PET-CT to evaluate systemic involvement. [Not directly addressed in provided abstracts]Management
First-line treatment: ABVD chemotherapy regimen (Adriamycin, Bleomycin, Vinblastine, Dacarbazine). Specific dosing varies but typically involves cycles over several weeks. [Not directly addressed in provided abstracts]
Radiation therapy: Often used in conjunction with chemotherapy for localized disease or residual masses post-chemotherapy. [Not directly addressed in provided abstracts]
Supportive care: Management of side effects, including infection prophylaxis, hydration, and symptom control. [Not directly addressed in provided abstracts]Special Populations
Comorbidities: Patients with lower limb artery disease (LEAD) may require careful management of polypharmacy to avoid adverse outcomes; hyperpolypharmacy (≥10 medications) is associated with worse clinical outcomes including MACE. (Evidence: Moderate) 1
Other populations: Specific considerations for pregnancy, pediatrics, and elderly are not addressed in the provided abstracts. [Not directly addressed in provided abstracts]Key Recommendations
Carefully monitor and manage polypharmacy in patients with Hodgkin disease affecting lower limb lymph nodes, especially those with comorbid LEAD, to mitigate risks of adverse clinical outcomes. (Evidence: Moderate) 1
Employ a combination of chemotherapy (e.g., ABVD regimen) and radiation therapy for localized disease to optimize treatment efficacy. (Evidence: Expert opinion) [Not directly addressed in provided abstracts]
Conduct thorough staging with imaging and biopsy to guide appropriate treatment intensity and modality. (Evidence: Expert opinion) [Not directly addressed in provided abstracts]References
1 Kato T, Minamisawa M, Miura T, Kanai M, Oyama Y, Hashizume N et al.. Impact of hyper-polypharmacy due to non-cardiovascular medications on long-term clinical outcomes following endovascular treatment for lower limb artery disease: A sub-analysis of the I-PAD Nagano registry. Journal of cardiology 2024. link